Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Q3 2025 Earnings Call Transcript
Operator: Good morning. My name is Carly, and I will be your conference operator today.
Amylyx Pharmaceuticals Inc. (AMLX)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Perceptive Advisors Joseph Edelman | 8,952,365 | $121,662,640 | +14% | 3.51% |
| 2. | Adage Capital Management Phill Gross And Robert Atchinson | 6,816,828 | $92,640,693 | -23% | 0.15% |
| 3. | Saturn V Capital Management Xiaoying Tian | 4,604,878 | $62,580,292 | +42% | 13.72% |
| 4. | Commodore Capital Egen Atkinson And Michael Kramarz | 4,075,478 | $55,385,746 | 2.7% | |
| 5. | Point72 Asset Management Steve Cohen | 2,790,066 | $37,916,998 | -39% | 0.06% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $3.70 | 10,000 | $37,005.00 | 10,000 | 2025-03-20 | Filing | |
| $2.53 | 40,000 | $101,368.00 | 233,464 | 2024-09-12 | Filing | |
| $2.13 | 50,000 | $106,590.00 | 55,000 | 2024-09-05 | Filing | |
| $2.20 | 100,000 | $219,800.00 | 858,571 | 2024-09-03 | Filing | |
| $1.89 | 2,250 | $4,252.28 | 5,000 | 2024-05-15 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $15.01 | 200 | $3,002.00 | 3,325,301 | 2025-09-30 | Filing | |
| $14.37 | 29,775 | $427,950.12 | 3,325,501 | 2025-09-30 | Filing | |
| $14.58 | 8,828 | $128,668.98 | 148,141 | 2025-09-30 | Filing | |
| $14.65 | 10,558 | $154,650.42 | 280,430 | 2025-09-30 | Filing | |
| $15.00 | 200 | $2,999.50 | 3,325,347 | 2025-09-30 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 11,379,207 | $154,643,424 | 0.01% | |
| 2. | 7,140,692 | $97,042,005 | 0% | |
| 3. | 5,273,750 | $71,670,263 | 0% | |
| 4. | 3,355,882 | $45,606,436 | 4.3% | |
| 5. | 2,536,233 | $34,454,725 | 0.02% |
News See All
BofA Securities Lifts Amylyx Pharmaceuticals Inc. (AMLX) Price Target Amid Bolstered Balance Sheet
Amylyx Pharmaceuticals Inc. (NASDAQ:AMLX) is one of billionaire Steve Cohen’s small-cap stock picks with huge upside potential.
Billionaire Steve Cohen's 10 Small-Cap Stock Picks with Huge Upside Potential
Known for speed, agility, and a high-risk, high-reward investment approach, Steve Cohen is one of the most successful hedge fund managers on Wall Street.
H.C. Wainwright, Leerink Partners, and TD Cowen Reaffirm ‘Buy’ Ratings on Amylyx Pharmaceuticals, Inc. (AMLX)
On August 8, 2025, H.C. Wainwright reaffirmed its ‘Buy’ rating on Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) with a $16 price target.
11 Best Single Digit Stocks to Buy According to Hedge Funds
The winning streak of U.S. stocks extended on Wednesday, August 13, 2025, with the S&P 500 and Nasdaq reaching fresh record highs for the second day in a row.
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Q2 2025 Earnings Call Transcript
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Q2 2025 Earnings Call Transcript August 7, 2025Amylyx Pharmaceuticals, Inc. misses on earnings expectations.
Amylyx Pharmaceuticals Shares Promising Avexitide Data for Post-Bariatric Hypoglycemia at ENDO 2025, Phase 3 Enrollment Nears Completion
Amylyx Pharmaceuticals Inc. (NASDAQ:AMLX) is one of the best low priced pharma stocks to buy now.
13 Best Low Priced Pharma Stocks to Buy Now
On July 9, Afsaneh Beschloss, RockCreek Group founder & CEO, joined 'Closing Bell Overtime' on CNBC to talk about the latest round of tariff threats.
Amylyx Pharmaceuticals Gains FDA Fast Track for ALS Drug AMX0114
Amylyx Pharmaceuticals Inc. (NASDAQ:AMLX) is one of the best biotech stocks to invest in now. On June 3, Amylyx Pharmaceuticals announced that the US FDA granted Fast Track designation to AMX0114.
13 Best Biotech Stocks To Invest In Now
In 2023, the global biotechnology market size was estimated at $1.55 trillion.